Patient-flow in the study.

<p>92 (69%) of the patients initially eligible for the study received a VL-result and were included in the final analysis. VL: viral load. ART: Anti-retroviral Therapy. WHO: World Health Organization.</p

The clinical score used in this study to predict viral failure.

<p>The score was originally developed in a Cambodian cohort <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0047937#pone.0047937-Lynen1" target="_blank">[9]</a>.</p>*<p>HAART, Highly Active Antiretroviral Therapy.</p>¶<p>Comparing current hemoglobin level to a documented hemoglobin measurement 3 to 9 months ago.</p

Characteristics of the 92 patients included in the analysis.

<p>IQR: inter-quartile range. ART: Anti-retroviral therapy. WHO: World Health Organization. HAART: Highly active anti-retroviral therapy. PMTCT: Prevention of mother-to-child transmission.</p

Positive predictive value of the clinical score and the WHO criteria.

<p> <b>Clinical score and WHO-criteria as predictors for a detectable viral load (≥40 copies) or viral failure (≥5’000 copies) among the 92 patients analysed for the study.</b></p><p>VL: Viral load. WHO: World Health Organization.</p